G
Grace Therapeutics, Inc. (GRCE)
NCM – Real vaqt narxi. Valyuta: USD
2.33
-0.02 (-0.85%)
Yopilishda: May 12, 2026, 4:00 PM EDT
2.26
-0.07 (-3.00%)
Bozor oldidan: May 13, 2026, 4:43 AM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
Find any stock by ticker or company name
NCM – Real vaqt narxi. Valyuta: USD
2.33
-0.02 (-0.85%)
Yopilishda: May 12, 2026, 4:00 PM EDT
2.26
-0.07 (-3.00%)
Bozor oldidan: May 13, 2026, 4:43 AM EDT
Grace Therapeutics, Inc. Kanadada kamyob va etim kasalliklar uchun farmatsevtika mahsulotlarini ishlab chiqish va tijoratlashtirish bilan shug'ullanadi. Kompaniyaning asosiy mahsulot nomzodi subaraxnoidal qon ketishni davolash uchun intravena infuzion bo'lgan GTX-104 hisoblanadi. Kompaniya, shuningdek, Ataksiya-Telangiektaziya (A-T) ning nevrologik alomatlarini yaxshilash uchun betametazonning og'iz orqali yuboriladigan shilliq qavat spreyi bo'lgan GTX-102 va postherpetik nevralgiya (PHN) bilan bog'liq og'riqlarni davolash uchun mahalliy bioadhesive plyonka hosil qiluvchi polimer bo'lgan GTX-101ni ishlab chiqadi. Kompaniya ilgari Acasti Pharma Inc. nomi bilan tanilgan va 2024 yil oktyabr oyida Grace Therapeutics, Inc. nomiga o'zgargan. Grace Therapeutics, Inc. 2002 yilda tashkil etilgan va Nyu-Jersi shtatining Prinston shahrida joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. R. Loch MacDonald M.D., Ph.D. | Member of Scientific Advisory Board & Chief Medical Officer |
| Mr. Amresh Kumar Ph.D. | VP of Program Management |
| Mr. Prashant Kohli | CEO & Director |
| Mr. Robert J. DelAversano CPA | VP of Finance and Principal Financial & Accounting Officer |
| Ms. Carrie D'Andrea | VP of Clinical Operations |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-04-27 | 8-K | ef20071554_8k.htm |
| 2026-04-23 | 8-K | ef20070593_8k.htm |
| 2026-02-12 | 10-Q | ef20060621_10q.htm |
| 2026-01-12 | 8-K | ef20062691_8k.htm |
| 2025-11-17 | 10-Q/A | ef20059408_10qa.htm |
| 2025-11-13 | 8-K | ef20058656_8k.htm |
| 2025-10-23 | 8-K | ef20057547_8k.htm |
| 2025-09-18 | 8-K | ef20055717_8k.htm |
| 2025-09-12 | 8-K | ef20055483_8k.htm |
| 2025-08-27 | 8-K | ef20054617_8k.htm |